Lipid kinases are enzymes that play a critical role in both cell signaling and membrane trafficking by phosphorylating lipid ...

In this video from Clinical Trials at the Summit, Lejla Vajzovic, MD, FASRS, of Duke Eye Center, discusses tyrosine kinase inhibitors and gene therapy as different approaches for wet age-related ...

China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor ...

Panelist discusses how Bruton tyrosine kinase inhibitors fit into real-world practice with community physicians often using ...

Targeting SHP2 has emerged as a promising approach for treating cancers driven by receptor tyrosine kinases. Although allosteric SHP2 inhibitors have shown strong antitumor activity in preclinical ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

Panelist discusses how efficacy and safety data from trials like ELEVATE-TN and CLL14 inform treatment decisions, noting that while both regimens are effective, patients with 17p deletion tend to ...

The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton’s tyrosine ...

Exelixis (EXEL) moves to 'Buy' with a de-risked pipeline, strong financials, and breakthrough phase 3 results. See more analysis here.

A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.